- Home
- FATE
as of 01-28-2026 3:41pm EST
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 124.6M | IPO Year: | 2013 |
| Target Price: | $3.92 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $1.94 | Next Earning Date: | 03-04-2026 |
| Revenue: | $7,137,000 | Revenue Growth: | -46.92% |
| Revenue Growth (this year): | -52.48% | Revenue Growth (next year): | -25.54% |
AI-Powered FATE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Fate Therapeutics Inc. (FATE)
See Remarks
Avg Cost/Share
$1.06
Shares
10,589
Total Value
$11,275.17
Owned After
387,081
SEC Form 4
President and CEO
Avg Cost/Share
$1.07
Shares
5,190
Total Value
$5,557.45
Owned After
329,708
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| TAHL CINDY | FATE | See Remarks | Jan 9, 2026 | Sell | $1.06 | 10,589 | $11,275.17 | 387,081 | |
| Valamehr Bahram | FATE | President and CEO | Jan 9, 2026 | Sell | $1.07 | 5,190 | $5,557.45 | 329,708 |
Compare FATE vs Leading Stocks
See how FATE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FATE Fate Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.